| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Chemoprevention Branch, Cancer Prevention Research Program, Division of Cancer Prevention and Control, National Cancer Institute, NIH, Bethesda, Maryland 20892
Intraepithelial neoplasia is of critical importance to the cancer chemoprevention field because it is a target condition for which drugs must be sought that will prevent its development or stop its progression. The term "dysplasia" refers to the morphological alterations that characterize intraepithelial neoplasia and according to many authors consists of seven basic morphological changes that occur in the majority of human epithelia, as well as in the epithelium of mouse skin papillomas induced by 7,12-dimethylbenz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate: increased nuclear size; altered nuclear shape; increased nuclear stain uptake; nuclear pleomorphism (increased variation in nuclear size, shape, and stain uptake); increased mitoses; abnormal mitoses; and disordered or absent maturation. Clonal evolution appears to begin early in the neoplastic process during intraepithelial neoplasia. Aneuploidy has been found during intraepithelial neoplasia in many human epithelia, and, in association with other forms of genetic instability, may provide the increase in genetically variant cells required for clonal evolution to occur. It is postulated that two major factors affecting the rate of progression of intraepithelial neoplasia are the cellular mutation rate, which is enhanced by environmental carcinogens, and the cellular proliferation rate, which is enhanced by agents that include sex hormones, inducers of chronic inflammation, and irritant chemicals which stimulate reactive hyperproliferation. A preferred chemoprevention strategy should consist of the development of drugs and drug combinations which will block mutagenic carcinogens or prevent epithelial hyperproliferation or its causes. Two examples of the induction of regression of intraepithelial neoplasia by chemopreventive drugs are the regression of oral leukoplakia produced by ß-carotene and the regression of colorectal polyps in patients with familial polyposis produced by sulindac. It is evident that there is a strong need for more research on the induction of regression of intraepithelial neoplasia with chemopreventive agents. There is also a critical need to identify and develop biomarkers that correlate with the appearance and regression of intraepithelial neoplasia.
1 To whom requests for reprints should be addressed.
Received 7/11/91. Accepted 1/27/92.
This article has been cited by other articles:
|
|
 |
|
  J. G. Einspahr, M.-J. Xu, J. Warneke, K. Saboda, J. Ranger-Moore, P. Bozzo, L. Duckett, R. Goldman, P. Lin, J. Buckmeier, et al. Reproducibility and Expression of Skin Biomarkers in Sun-Damaged Skin and Actinic Keratoses Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1841 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yang, N. H. Varvel, B. T. Lamb, and K. Herrup Ectopic Cell Cycle Events Link Human Alzheimer's Disease and Amyloid Precursor Protein Transgenic Mouse Models J. Neurosci., January 18, 2006; 26(3): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Denkins, D. Kempf, M. Ferniz, S. Nileshwar, and D. Marchetti Role of {omega}-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma J. Lipid Res., June 1, 2005; 46(6): 1278 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs Clin. Cancer Res., June 1, 2004; 10(11): 3908 - 3918. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Singletary, E. N. Atkinson, A. Hoque, N. Sneige, A. A. Sahin, H. A. Fritsche Jr., R. Lotan, T. Lu, W. N. Hittelman, T. B. Bevers, et al. Phase II Clinical Trial of N-(4-Hydroxyphenyl)retinamide and Tamoxifen Administration before Definitive Surgery for Breast Neoplasia Clin. Cancer Res., September 1, 2002; 8(9): 2835 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lam, C. MacAulay, J. C. le Riche, Y. Dyachkova, A. Coldman, M. Guillaud, E. Hawk, M.-O. Christen, and A. F. Gazdar A Randomized Phase IIb Trial of Anethole Dithiolethione in Smokers with Bronchial Dysplasia J Natl Cancer Inst, July 3, 2002; 94(13): 1001 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Q. Shyong, Y. Lu, A. Lazinsky, R. N. Saladi, R. G. Phelps, L. M. Austin, M. Lebwohl, and H. Wei Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage Carcinogenesis, February 1, 2002; 23(2): 317 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon, A. J. Dannenberg, W. K. Hong, C. J. Fabian, C. C. Sigman, M. M. Bertagnolli, S. P. Stratton, S. Lam, et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development : Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia Clin. Cancer Res., February 1, 2002; 8(2): 314 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Stoner and A. Gupta Etiology and chemoprevention of esophageal squamous cell carcinoma Carcinogenesis, November 1, 2001; 22(11): 1737 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Follen, F. L. Meyskens Jr., E. N. Atkinson, and D. Schottenfeld Why Most Randomized Phase II Cervical Cancer Chemoprevention Trials are Uninformative: Lessons for the Future J Natl Cancer Inst, September 5, 2001; 93(17): 1293 - 1296. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Boone, G. D. Stoner, J. V. Bacus, V. Kagan, M. A. Morse, G. J. Kelloff, and J. W. Bacus Quantitative Grading of Rat Esophageal Carcinogenesis Using Computer-assisted Image Tile Analysis Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 495 - 500. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Kelloff, C. C. Sigman, K. M. Johnson, C. W. Boone, P. Greenwald, J. A. Crowell, E. T. Hawk, and L. A. Doody Perspectives on Surrogate End Points in the Development of Drugs that Reduce the Risk of Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 127 - 137. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Bacus, C. W. Boone, J. V. Bacus, M. Follen, G. J. Kelloff, V. Kagan, and S. M. Lippman Image Morphometric Nuclear Grading of Intraepithelial Neoplastic Lesions with Applications to Cancer Chemoprevention Trials Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1087 - 1094. [Abstract] [Full Text]
|
|
|
|
|
|
U. Veronesi, G. De Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. R. Del Turco, M. G. Di Mauro, et al. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1847 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng, P. M. Kramer, R. A. Lubet, V. E. Steele, G. J. Kelloff, and M. A. Pereira Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci Carcinogenesis, February 1, 1999; 20(2): 255 - 260. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
